FPT Named an OpenAI Select Partner
6.8.2026 03:00:00 EEST | Business Wire | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/
FPT Named an OpenAI Select Partner
The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact.
As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into finished work. Combining AI-native engineering, enterprise integration expertise, and large-scale delivery capabilities, FPT brings frontier AI technologies into real-world operations with speed and control.
“As an OpenAI Select Partner, FPT will continue working with OpenAI to bring frontier models and products into enterprise operations at scale, helping organizations accelerate AI transformation responsibly and effectively,” said Pham Minh Tuan, FPT Software Chief Executive Officer and Executive Vice President, FPT Corporation.
“Cybersecurity is a critical area where frontier AI can create significant impact. By integrating GPT-5.6 Sol and Codex Security frontier intelligence into FPT’s cybersecurity platforms and intelligent workflows, especially our Patch the Enterprise program, we proactively protect our customers' IT infrastructure and application environments as new AI-related risks emerge. This empowers organizations to identify, prioritize, and remediate vulnerabilities more efficiently while addressing emerging security risks with greater resilience and confidence,” he added.
Looking ahead, FPT plans to further integrate OpenAI technologies across its FleziPT ecosystem, develop new agentic AI solutions for enterprise workflows, expand AI infrastructure and enablement programs, and redesign operations around human–AI collaboration and AI-native ways of working, helping customers translate AI ambition into business outcomes.
FPT’s AI-first approach is guided by CASAN, an enterprise transformation framework designed to help organizations progress from fragmented experimentation to scalable, real-world AI deployment. Built around five levels of AI maturity—Curious, Augmented, Standard, Automatic, and Native—CASAN provides a structured roadmap to assess AI readiness, strengthen governance, and operationalize AI across core business functions. The framework is designed to address the challenges many enterprises face in effectively scaling AI by helping them assess their AI maturity, define the right adoption path, and transition from isolated initiatives to AI-native operations that deliver tangible value.
To support this vision, FPT has built an AI ecosystem comprising the AI platform, FleziPT, AI Factories in Vietnam and Japan, and a global workforce of more than 30,000 AI-augmented engineers, as well as strategic partnerships with leading AI players. Together, these capabilities enable FPT to deliver AI transformation at scale with tailored solutions that improve quality, speed, scalability, and traceability, delivering up to 60% shorter development time, more than 50% less rework, and a 30% uplift in developer productivity.
Learn more about the OpenAI Partner Network: https://openai.com/business/partners/
About FPT Corporation
FPT Corporation (FPT) is a globally leading Vietnam-headquartered technology and IT services provider, with operations spanning more than 30 countries and territories. Over more than three decades, FPT has consistently delivered impactful solutions to millions of individuals and tens of thousands of organizations worldwide. With a strong focus on mastering strategic technologies, FPT continues to drive innovation across industries. As an AI-first company, FPT is committed to elevating Vietnam’s position on the global tech map and delivering world-class AI-enabled solutions for global enterprises. In 2025, FPT reported a total revenue of USD 2.66 billion and a workforce of over 54,000 employees across its core businesses.
For more information about FPT's global IT services, please visit https://fptsoftware.com/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260805503787/en/
Contacts
Media Contact
Mai Duong (Ms.)
FPT Corporation
FPT Software PR Manager
MCP.PR@fpt.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 17:05:00 EEST | Press release
Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership, and operational excellence with a track record of execution from first-in-human studies through regulatory
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
Speech Processing Solutions Launches Philips SpeechLive Legal AI Assistant for Faster, More Accurate Legal Document Creation5.8.2026 16:37:00 EEST | Press release
Speech Processing Solutions, the global leader in AI-assisted professional dictation and documentation solutions sold under the Philips brand, today announced the Philips SpeechLive Legal AI Assistant. The new solution transforms voice recordings, dictation and uploaded sources into structured, ready-to-review legal documents, helping legal professionals work faster while retaining control of the final draft. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805997413/en/ The new Philips SpeechLive Legal AI Assistant is designed for turning conversations into ready-to-review legal document drafts. SpeechLive Legal significantly reduces the time needed to transform voice input into structured legal documentation, delivering consistent and high-quality drafts and featuring SpeechLive's built-in integrations with leading case management platforms such as Actionstep, Clio, iManage and NetDocuments, supporting existing billing, e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom